Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

InspireMD Q3 2026 Results: Net Loss of $9.76M, Loss Narrows

InspireMD reported a net loss of $37.8 million for the nine months ended September 30, 2026, compared to $37.0 million in the prior year period. While revenues grew to $7.4 million from $5.8 million year-over-year, the company experienced a significant decrease in cash and marketable securities, ending the period with $19.2 million in cash.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.22.5
Gross profit0.20.9
Net income-9.8-12.7
EPS (diluted, $ a share)$-0.12$-0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-11.1%
Gross margin10.7%
Operating margin-443.9%
Source

10-Q filed with the SEC, NASDAQ: NSPR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

InspireMD, Inc.: key numbers

Share price
$0.6000Close, Nov 16
Market cap
$32.5M
Shares outstanding
54.13MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from InspireMD, Inc.

All →
7:06 AM ET 8-K
Capital Raise

InspireMD Capital Raise of $37.5M

InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.

Value
$37.5M
Counterparty
Lake Street Capital Markets, LLC
4:46 PM ET 8-K
Financial Results

InspireMD Financial Results

InspireMD reported third quarter 2026 financial results, highlighted by total revenue of $2.2 million, a 9% increase year-over-year driven by international performance. During the quarter, the company received FDA approval for its CGuard Prime carotid stent system for TCAR procedures, which is expected to double its U.S. addressable market with a commercial launch planned for Q4 2026.

Term
Q3 2026

“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-g”

Marvin Slosman, Chief Executive Officer
4:46 PM ET 8-K
Regulatory Approval

InspireMD Regulatory Approval

InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.

9:12 AM ET 8-K
Loan & Debt

InspireMD $11M Debt Financing

InspireMD entered into amendments with holders of its Series J and Series K warrants to align their exercise triggers with the anticipated Q4 2026 FDA approval of the CGuard Prime 80 cm. The amendments modify the exercise price to $0.7674 per share for approximately 14.3 million underlying shares, potentially providing up to $11 million in gross proceeds to fund the product launch. The new expiration date is set for 20 trading days following the announcement of FDA approval or May 15, 2028.

Value
$11M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.